腺体原位先天性甲状腺功能减退症的临床病程及重新评估后左甲状腺素治疗的必要性
该回顾性研究纳入77例新生儿筛查阳性后确诊的腺体原位先天性甲状腺功能减退症患儿,3岁时55例停药后重新评估,49例有充足随访数据,结果显示49%的患者已停止治疗,51%仍在服药;永久性先天性甲状腺功能减退症患者末次停药试验前左甲状腺素剂量更高(P=0.016)。作者认为需要监测甲状腺功能以评估替代治疗必要性并避免过度治疗,即使可暂停治疗也需监测,因为停药后数月甲状腺功能可能下降。
要点
- 腺体原位先天性甲状腺功能减退症患儿3岁时可尝试停药重新评估。
- 重新评估的55例中18例(32.7%)甲状腺功能正常。
- 随访中49%的患者已停止治疗,51%仍在服药。
核心结论
- 对腺体原位先天性甲状腺功能减退症患儿监测甲状腺功能是必要的,以评估替代治疗需求并避免过度治疗。
- 即使治疗可以暂停,患者仍需监测,因为停药后数月甲状腺功能可能下降。
研究设计与样本
- 回顾性评估在比萨先天性甲状腺功能减退症转诊区域中心随访的患者。
- 纳入77例新生儿筛查阳性后确诊的腺体原位原发性先天性甲状腺功能减退症患儿,所有患儿在血清检测确认后开始左甲状腺素治疗。
- 55例患儿在3岁时停药后进行临床重新评估,包括激素检查、甲状腺超声和123碘-过氯酸盐排泌试验。
- 49例患者有充足随访数据(停药试验后至少6个月)。
主要发现
- 重新评估的55例患者中,18例(32.7%)甲状腺功能正常。
- 考虑后续随访,49%的患者已不再治疗,51%仍在接受治疗。
- 两组新生儿参数无差异。
- 永久性先天性甲状腺功能减退症患者末次停药试验前左甲状腺素剂量更高(P=0.016)。
临床怎么用
- 作者认为,对腺体原位先天性甲状腺功能减退症患儿监测甲状腺功能是必要的,以评估替代治疗需求并避免过度治疗。
- 作者指出,即使治疗可以暂停,患者仍需监测,因为停药后数月甲状腺功能可能下降。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The clinical course and need for long-term L-thyroxine (LT4) therapy of congenital hypothyroidism (CH) with gland in situ (GIS) remain unclear. OBJECTIVE: To describe the clinical history of CH with GIS and evaluate the proportion of patients who can suspend therapy during follow-up. DESIGN AND SETTING: Retrospective evaluation of patients followed at referral regional center for CH of Pisa. PATIENTS: Seventy-seven patients with confirmed primary CH and GIS after positive neonatal screening were included. All children started LT4 upon CH confirmation on serum assay. INTERVENTIONS: At 3 years of age, 55 children underwent a clinical reevaluation after withdrawal of therapy with hormonal examinations, imaging of the thyroid gland with ultrasonography, and 123-iodine with perchlorate discharge test. Subsequent periodic controls of thyroid function were executed, and, when possible, a new attempt to stop LT4 was performed. Adequate follow-up data (at least 6 months after treatment suspension trial) were available for 49 patients. RESULTS: Among the 55 patients who were reassessed, 18 (32.7%) were euthyroid. Considering subsequent follow-up, 49% of patients were no longer treated and 51% were taking therapy. No differences in neonatal parameters were observed between the 2 groups; LT4 dose before the last trial off medication was higher in permanent CH (P .016). CONCLUSION: Monitoring thyroid function in children with CH and GIS is necessary to evaluate the need for substitution and avoid overtreatment. Even if therapy can be suspended, patients need to be monitored because apparently normal thyroid function may decline several months after withdrawal of LT4.
引用
- Pignata L, Bagattini B, Di Cosmo C, et al. Clinical Course of Congenital Hypothyroidism With Gland In Situ and Necessity of L-Thyroxine Therapy After Re-evaluation. J Clin Endocrinol Metab. 2025. PMID: 38986013. doi:10.1210/clinem/dgae471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。